PROCF.US Sofgen Pharma S.A.
- Market cap
- USD 29.2M
- P/E
- -
- P/B
- 66.68x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2024.
Is PROCF.US undervalued?
Graham numberThe Graham number of Sofgen Pharma S.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sofgen Pharma S.A. fundamental analysis
No fundamental analysis for Sofgen Pharma S.A. yet.
Sofgen Pharma S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sofgen Pharma S.A.
Sofgen Pharma S.A., together with its subsidiaries, develops, produces, and markets pharmaceutical solutions in South America, Central America, North America, and Europe. It operates in five segments: NextGel, Procaps Colombia, Central America North (CAN), Central America South and North Andes (CASAND), and Diabetrics. The company develops and manufactures Softgel and related technologies under the Softigel, Sofgen, Softcaps, and Funtrition brands; and Softgel pharmaceutical…
Full company profileSofgen Pharma S.A. financial statements
Sofgen Pharma S.A. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 404M | 403M | 424M | 374M |
| Gross Profit | 230M | 235M | 238M | 191M |
| Operating Income | 65.1M | 36.3M | 44.3M | -32.5M |
| EBITDA | 6.79M | 90.4M | 105M | -22.1M |
| Net Income | -107M | 36.1M | 40.3M | -68.3M |
| EPS | -0.95 | 0.32 | 0.40 | -0.61 |
| Balance Sheet | ||||
| Total Assets | 450M | 443M | 472M | 412M |
| Total Liabilities | 520M | 480M | 473M | 464M |
| Shareholders' Equity | -69.0M | -36.2M | 210K | -51.1M |
| Cash & Short-term Investments | 72.1M | 43.0M | 17.5M | 30.3M |
| Cash Flow | ||||
| Operating Cash Flow | 35.5M | 15.6M | 108M | 88.4M |
| Capital Expenditure | 25.8M | 34.1M | 32.8M | 25.0M |
| Free Cash Flow | 9.61M | -18.6M | 74.8M | 63.4M |
| Ratios | ||||
| ROE | - | - | 19,211.0% | - |
| ROA | -23.8% | 8.2% | 8.5% | -16.6% |
| Net Profit Margin | -26.5% | 9.0% | 9.5% | -18.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sofgen Pharma S.A. dividends
Sofgen Pharma S.A. has not paid dividends in the last 5 fiscal years.
Who owns Sofgen Pharma S.A.
- Insiders 89.27%
- Institutions 0.12%
- Public & others 10.61%
- Shares outstanding 2.33B
- Free float 1.35B
Sofgen Pharma S.A. company profile
- Company name
- Sofgen Pharma S.A.
- Ticker
- PROCF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 4,498
- Fiscal year end
- December
- Address
- 9 Rue de Bitbourg, Luxembourg, Luxembourg, 1273
- Phone
- 356 7995 6138
- Website
- sofgenpharma.com
About Sofgen Pharma S.A.
Sofgen Pharma S.A., together with its subsidiaries, develops, produces, and markets pharmaceutical solutions in South America, Central America, North America, and Europe. It operates in five segments: NextGel, Procaps Colombia, Central America North (CAN), Central America South and North Andes (CASAND), and Diabetrics. The company develops and manufactures Softgel and related technologies under the Softigel, Sofgen, Softcaps, and Funtrition brands; and Softgel pharmaceutical products, such as Advil, Apronax Liquidgels, multivitamins, Vitamin D, and Dolex ActivGel. It also formulates, manufactures, and markets branded prescription drugs in therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory; and manufactures and markets personal high-complexity drugs for hospital use comprising antibiotics, blood clot, immunosuppressant, oncology, and analgesics products. In addition, the company develops, manufactures, and markets OTC consumer healthcare products consisting of gastrointestinal, skin care, cough and cold, analgesics, urological, and vitamin, minerals, and supplements, as well as antibiotics, anti-infective, and anti-parasitic. Further, it offers blood glucose meters, telemonitoring, Rx oral anti-diabetics products, insulin delivery systems, and other diabetes solutions; and syringes, double chamber syringes, injection vials, injection ampoules, sterilized powder products, sterile droppers, and lyophilized solid vials. The company was formerly known as Procaps Group S.A. Sofgen Pharma S.A. was founded in 1977 and is based in Luxembourg, Luxembourg.
Sofgen Pharma S.A. management
3- Mr. Ruben MinskiCEO &Chairman of the Board · born 1952
- Mr. Daniel BernalInterim Chief Financial Officer · born 1976
- Mr. Luis Alberto Palacios AragonChief Commercial Officer · born 1965